September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Li­for­di Im­munother­a­peu­tics: Us­ing an­ti­bod­ies to de­liv­er po­tent steroids di­rect­ly to im­mune cells

Ryan Cross

Senior Science Correspondent

↑
  • CEO Arthur Tzian­a­bos
  • To­tal raised $70 mil­lion
  • Head­quar­ters Burling­ton, MA

As a young sci­en­tist, Jay Roth­stein asked fel­low im­mu­nol­o­gists what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times